Non-Clinical Research Studies

PAH Patient Evidence Submission Survey: sotatercept

PHA Canada, along with our partners at Scleroderma Ontario, Sclerodermie Quebec, and Foundation HTAPQ, is conducting a survey to learn how current pulmonary arterial hypertension (PAH) therapies affect you and your expectations for the new PAH therapy sotatercept. You are invited to participate in this survey if you are a PAH patient or caregiver residing in Canada.

Back to Non-Clinical Research Studies

The survey results will be included in the patient/caregiver input we will provide to Canada/Quebec’s health technology assessment agencies – e.g., CADTH and INESSS.

Survey closes: March 31, 2024

If you would like more information about the survey or our submissions regarding sotatercept, please get in touch with PHA Canada Executive Director Jamie Myrah at jmyrah@phacanada.ca.